Echo Therapeutics, a developer of needle-free Symphony transdermal continuous glucose monitoring (CGM) system, has obtained ISO 13485:2003 certification for its quality management system.
Symphony transdermal CGM system provides accurate, real-time blood glucose data conveniently, continuously and cost-effectively, claims the company.
Echo Therapeutics quality assurance vice president Stephen Perez said the certification demonstrates the company's continued commitment to meet and exceed the high standards required of medical device companies selling into Europe.
"We believe that receiving ISO 13485 certification is a significant accomplishment and an important milestone as we approach the European pivotal trial and commercialization of our Symphony CGM System," Perez added.
